Clinical Trial Update: Safety, Efficacy and Cellular Metabolic Dynamics of CT1195E in Patients With Refractory / Progressive SSC [EARLY_Phase 1]

View source ↗

Summary

An early Phase 1 trial update for CT1195E in patients with refractory or progressive systemic sclerosis, with recruitment ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Sclerosis

Drugs mentioned

• CT1195E

Snippet

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Conditions: SSc-Systemic Sclerosis | EARLY_Phase 1 | Status: RECRUITING